BOULDER, Colo., May 28, 2015 /PRNewswire/ -- Array BioPharma
Inc. (NASDAQ: ARRY) today announced presentations on encorafenib,
binimetinib and selumetinib (licensed to AstraZeneca) at the 2015
American Society of Clinical Oncology (ASCO) Annual Meeting, which
will be held May 29 – June 2, 2015 in Chicago, Illinois. These three products
are currently advancing in a total of 6 pivotal trials, with
top-line results expected in 2015 from both the NEMO (binimetinib
monotherapy in NRAS mutant melanoma patients) and SUMIT
(selumetinib with dacarbazine in uveal melanoma patients) Phase 3
trials.
Ron Squarer, Chief Executive Officer of Array, noted, "We are
encouraged to see eight ASCO abstracts reporting clinical results
from Array-invented BRAF, MEK and HER2 drugs, while we await
readouts later this year from two pivotal trials, NEMO and
SUMIT."
The following is a summary of the presentations that will be
given at ASCO:
ORAL PRESENTATIONS
|
|
Title:
|
A phase Ib/II study
of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK
inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma
patients naive to BRAFi treatment (Abstract
#9007)
|
Presenter:
|
Ryan J. Sullivan,
MD
|
Date:
|
Saturday, May 30,
3:27 - 3:39 p.m. CDT (Oral Presentation)
|
|
|
Title:
|
A phase Ib/II study
of MEK162 (binimetinib [BINI]) in combination with imatinib
in patients with advanced gastrointestinal stromal tumor (GIST)
(Abstract #10507)
|
Presenter:
|
Ping Chi, MD,
PhD
|
Date:
|
Monday, June 1, 5:12
- 5:24 p.m. CDT (Oral Presentation)
|
POSTER PRESENTATIONS
Title:
|
A phase Ib
dose-escalation study of binimetinib (MEK162) in combination
with weekly paclitaxel in patients with platinum-resistant
epithelial ovarian, fallopian tube or primary peritoneal cancer
(Abstract #9051)
|
Presenter:
|
Rachel N. Grisham,
MD
|
Date:
|
Saturday, May 30,
1:15 - 4:45 p.m. CDT
|
Abstract #9051
will also be discussed at the Poster Discussion Session on
Saturday, May 30, 4:45 - 6:00 p.m.
|
|
|
Title:
|
Preliminary results
of TATTON, a multi-arm phase Ib trial of AZD9291 combined with
MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer
(Abstract #2509)
|
Presenter:
|
Geoffrey R. Oxnard,
MD
|
Date:
|
Saturday, May 30,
1:15 – 2:30 p.m. CDT
|
|
|
Title:
|
A phase I dose
escalation study of the tolerability of the oral VEGFR and EGFR
inhibitor vandetanib (V) in combination with the oral MEK inhibitor
selumetinib (S) in solid tumors (Abstract
#2583)
|
Presenter:
|
Wasiru Olugbenga
Saka
|
Date:
|
Saturday, May 30,
1:15 – 2:30 p.m. CDT
|
|
|
Title:
|
SWOG S1115:
Randomized phase II trial of selumetinib (AZD6244; ARRY
142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs.
mFOLFOX in pretreated patients (Pts) with metastatic pancreatic
cancer (Abstract #4119)
|
Presenter:
|
Vincent M. Chung,
MD
|
Date:
|
Monday, June 1, 8 –
11:30 a.m. CDT
|
|
|
Title:
|
A phase Ib study of
selumetinib in patients (pts) with previously untreated
metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard
chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197
(Abstract #8046)
|
Presenter:
|
Garth Andrew
Nicholas, MD
|
Date:
|
Monday, June 1, 8 –
11:30 a.m. CDT
|
|
|
Title:
|
ONT-380 in the
treatment of HER2+ breast cancer central nervous system (CNS)
metastases (mets) (Abstract #612)
|
Presenter:
|
Cristiano Ferrario,
MD
|
Date:
|
Saturday, May 30, 8 –
11:30 a.m. CDT
|
Trials in Progress posters will also showcase the trial designs
for the Phase 3 binimetinib trial in low-grade serous ovarian
cancer (MILO), two filanesib Phase 2 trials in multiple myeloma
(combination with carfilzomib, and single agent (AfFIRM), two
ipatasertib (GDC-0068) Phase 2 trials in breast cancer (FAIRLANE
and LOTUS) and the LOXO-101 Phase 1 trial in solid
tumors.
All abstracts can be accessed through the ASCO website,
http://abstract.asco.org/. After the presentations and
posters are public, they will be available as PDFs on Array's
website at www.arraybiopharma.com.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat patients afflicted with cancer. Six
Phase 3 studies are currently advancing. These programs include
three cancer drugs, binimetinib (MEK162 / wholly-owned),
encorafenib (LGX818 / wholly-owned) and selumetinib
(AstraZeneca). For more information on Array, please go to
www.arraybiopharma.com.
CONTACT:
|
Tricia
Haugeto
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentations-at-the-2015-asco-annual-meeting-300089644.html
SOURCE Array BioPharma Inc.